These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9732829)

  • 1. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discusion 47. PubMed ID: 9732829
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discussion 47. PubMed ID: 9732825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia].
    Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of lower urinary tract symptoms with combined medical therapy.
    Roehrborn CG
    BJU Int; 2008 Nov; 102 Suppl 2():13-7. PubMed ID: 19032605
    [No Abstract]   [Full Text] [Related]  

  • 7. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy of benign prostatic hyperplasia].
    Vahlensieck W; Fabricius PG; Hell U
    Fortschr Med; 1996 Nov; 114(31):407-11. PubMed ID: 9036092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation?
    Michel MC; Schafers RF; Goepel M
    BJU Int; 2000 Oct; 86 Suppl 2():23-8; discussion 28-30. PubMed ID: 11501614
    [No Abstract]   [Full Text] [Related]  

  • 12. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 15. [Urodynamic study of lower urinary tract. VI. Clinical application of alpha adrenergic blocker for the treatment of benign prostatic hypertrophy and bladder neck contracture (author's transl)].
    Kondo A; Narita H; Otani T; Kobayashi M; Takita T
    Nihon Hinyokika Gakkai Zasshi; 1978 Oct; 69(10):1232-40. PubMed ID: 83419
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
    Von Heland M; Casale P
    Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of alpha blockers in BPH.
    Jardin A
    Prog Clin Biol Res; 1994; 386():279-83. PubMed ID: 7528395
    [No Abstract]   [Full Text] [Related]  

  • 19. Benign prostatic hyperplasia: maximizing treatment with alpha blockers.
    Lowenthal DT; Flannery M; Mader SL; Nelson RP
    Geriatrics; 1998 Oct; 53 Suppl 2():S4-28. PubMed ID: 9789482
    [No Abstract]   [Full Text] [Related]  

  • 20. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.